MilliporeSigma acquires AmpTec

By The Science Advisory Board staff writers

January 7, 2021 -- MilliporeSigma has purchased messenger RNA (mRNA) firm AmpTec. The deal is expected to boost MilliporeSigma's ability to develop and manufacture mRNA for use in COVID-19 vaccines and treatments.

AmpTec's polymerase chain reaction (PCR)-based technology has benefits over other technologies for mRNA manufacturing, including better homogeneity, purity, and activity and improved performance, according to MilliporeSigma. As well, AmpTec's diagnostics business, which produces customized long RNAs and DNAs for in vitro diagnostics, will complement MilliporeSigma's own diagnostics business, it said.

MilliporeSigma invests $47M in U.S. biomanufacturing facilities
MilliporeSigma is increasing its manufacturing footprint in the U.S. with a $47 million investment in its Danvers, MA, and Jaffrey, NH, biomanufacturing...
MilliporeSigma holds topping-out ceremony for new membrane plant
MilliporeSigma celebrated the topping out of its new membrane production plant in Darmstadt, Germany, with a ceremony on October 8.
MilliporeSigma expands antibody-drug conjugate manufacturing
MilliporeSigma is expanding its high-potent active pharmaceutical ingredient and antibody-drug conjugate manufacturing capabilities with a $65 million...
MIT, MilliporeSigma create Pandemic Response CoLab
The Massachusetts Institute of Technology (MIT) has launched Pandemic Response CoLab with the goal of bringing together innovators from around the globe...
MilliporeSigma, Baylor partnering on COVID-19 vaccine
MilliporeSigma and Baylor College of Medicine have announced they are working to advance a vaccine manufacturing platform to fight COVID-19. The partnership...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter